Regeneron: Outpatient trial had positive results
Regeneron Pharmaceuticals Inc. announced on Wednesday that the data from “the Phase 2/3 seamless trial in the COVID-19 outpatient setting” demonstrated that the company’s investigational antibody cocktail REGN-COV2 “significantly reduced viral load and patient medical visits.”
The latest trial included 524 participants, almost double compared to 275 from the previous one, and showed that “the trial met all of the first nine endpoints in the statistical hierarchy.”
“Regeneron has shared these results with the US Food and Drug Administration as part of its review of our Emergency Use Authorization submission, and we continue to focus on completing our ongoing trials evaluating REGN-COV2 for the treatment and prevention of COVID-19,” President and Chief Scientific Officer Dr. George Yancopoulos said in the press release.
The company’s shares jumped 2.64% in after-hours trading after the findings were published.
Get involved!
Comments